(via TheNewswire)
Dear Shareholders,
I would first like to thank all our shareholders for their support of GeneTether. Despite many negative macro environment factors, there are many reasons why I'm excited to be sharing our update with you.
I think we all agree that the equity markets in general, and the biotech sector in particular, have been hit really hard over the past 12 months due to multiple factors, including the pandemic, inflation, the conflict in
As a reminder, our innovative, proprietary platform technology has shown to significantly increase the efficiency of DNA insertion into the genome. We believe that our technology, which showed a 7x higher gene editing efficiency in our proof-of-concept study, applies to most gene correction/gene complementation strategies, regardless of organ or disease. This creates numerous opportunities to partner with other gene editing companies that are focused on gene correction and complementation.
We have a very strong IP portfolio that is wholly owned and is comprised of composition of matter patents with broad claims. Last May, we received our patent in the
In addition to the patents currently issued in the
On the R&D front, we’ve recently pivoted our R&D efforts towards advancing our programs in-house versus outsourcing most activities. This allows us to preserve cash and exert greater control over experimental designs and development of protocols. We believe this will increase efficiencies and significantly de-risk any future outsourced R&D activities.
In August, we secured space in the new
One area of interest for us is related to chronic kidney disease (CKD). There are 625 known genetically driven monogenic disorders associated with kidney and urological traits. We believe our technology may allow us to develop gene medicine-based treatments for common subtypes of both autosomal dominant tubulo-interstitial kidney disease (ADTKD) and autosomal dominant polycystic kidney disease (ADPKD). Our main current R&D efforts are concentrated on the most common form of ADTKD caused by mutations in the uromodulin gene (UMOD). We believe a gene correction approach will offer a curative treatment for this disorder for which there is no current treatment beyond symptom management or kidney transplant.
As we progress towards IND-enabling studies, we are exploring some novel types of preclinical studies, which would include collaborations with scientists at the cutting edge of chronic kidney diseases and other third parties. I expect to be able to share more details on our R&D plan as it continues to advance.
As you can see, we’re extremely excited about GeneTether’s potential and I look forward to keeping you all informed.
Best regards,
For the most recent corporate presentation, visit www.genetether.com.
About GeneTether
Founded by
For more information, visit www.genetether.com.
Contacts:
(833) 294-4363 ext. 1
roland@genetether.com
(833) 294-4363 ext. 2
jean@genetether.com
Forward-Looking Disclaimer
This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause GeneTether’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.
Forward-looking statements in this document include the expectation that the Company will significantly advance its research and development plan, expectations that the Company will develop collaboration opportunities with other genetic medicines companies, the expectation that the GeneTetherTMplatform technology applies to most other gene correction/gene complementation strategies regardless of organ or disease, expectations that advancing our programs in-house will help us preserve cash and exert greater control over designs and development protocols, and all other statements that are not statements of historical fact.
Although GeneTether believes the forward-looking information contained in this news release is reasonable based on information available on the date hereof, by their nature forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. By their nature, these statements involve a variety of assumptions, known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such statements.
Examples of such assumptions, risks and uncertainties include, without limitation, assumptions, risks and uncertainties associated withthe global COVID-19 pandemic;general economic conditions; adverse industry events; future legislative and regulatory developments; the Company’s ability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the ability of GeneTether to implement its business strategies; competition; the ability of GeneTether to obtain and retain all applicable regulatory approvals and other assumptions, risks and uncertainties, including those set forth under the heading “Risk Factors” in the Company’s final prospectus dated
THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS NEWS RELEASE REPRESENTS THE EXPECTATIONS OF THE COMPANY AS OF THE DATE OF THIS NEWS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE THE COMPANY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE LAWS.
The Canadian Securities Exchange nor its Regulation Service has approved nor disapproved the contents of this news release
Copyright (c) 2022 TheNewswire - All rights reserved.
Copyright (c) 2022 TheNewswire - All rights reserved., source